<?xml version="1.1" encoding="UTF-8" standalone="yes"?><xml><head><creation_date>D:20210825105100Z</creation_date><modification_date>D:20221017143700Z</modification_date><initial_authorization>False</initial_authorization><pdf_file>EU-1-20-1492_h_dec_4.pdf</pdf_file></head><body><section><header>enen</header><p>european commission
 brussels, 15.11.2022c(2022) 8356 (final)</p></section><section><header>commission implementing decisionof 15.11.2022
 on the annual renewal of the conditional marketing authorisation for the orphan 
 medicinal product for human use &quot;tecartus - brexucabtagene autoleucel&quot;, granted by 
 decision c(2020) 9284(final)</header><p>(text with eea relevance) (only the dutch text is authentic)</p></section><section><header>en</header><p>1</p></section><section><header>en</header></section><section><header>commission implementing decisionof 15.11.2022
 on the annual renewal of the conditional marketing authorisation for the orphan 
 medicinal product for human use &quot;tecartus - brexucabtagene autoleucel&quot;, granted by 
 decision c(2020) 9284(final)</header><p>(text with eea relevance)(only the dutch text is authentic)
 the european commission,
 having regard to the treaty on the functioning of the european union,
 having regard to regulation (ec) no 726/2004 of the european parliament and of the 
 council of 31 march 2004 laying down union procedures for the authorisation and 
 supervision of medicinal products for human use and establishing a european medicines 
 agency
 1, and in particular article 10(2) and 14-a thereof,having regard to commission regulation (ec) no 507/2006 on the conditional marketing 
 authorisation for medicinal products for human use falling within the scope of regulation 
 (ec) no 726/2004 of the european parliament and of the council
 2,having regard to the application submitted by kite pharma eu b.v., on 6 june 2022, under 
 article 6(2) of regulation (ec) no 507/2006 with a view to the annual renewal of the 
 conditional marketing authorisation for the medicinal product &quot;tecartus - brexucabtagene 
 autoleucel&quot;,
 having regard to the opinion of the european medicines agency, formulated on 15 
 september 2022 by the committee for medicinal products for human use,
 whereas:
 (1)
 the medicinal product &quot;tecartus - brexucabtagene autoleucel&quot;, entered in the union 
 register of medicinal products under the number eu/1/20/1492 and authorised by 
 commission decision c(2020) 9284(final) of 14 december 2020, remains in 
 compliance with the requirements of article 14-a of regulation (ec) no 726/2004 of 
 the european parliament and of the council, and regulation (ec) no 507/2006,
 (2)
 the conditional marketing authorisation granted by decision c(2020) 9284(final) 
 should therefore be renewed.
 (3)
 the union register of medicinal products should be updated.
 (4)
 the measures provided for in this decision are in accordance with the opinion of the 
 standing committee on medicinal products for human use,
 1oj l 136, 30.4.2004, p. 1.2oj l 92, 30.3.2006, p. 6.</p></section><section><header>en</header><p>2</p></section><section><header>en</header><p>has adopted this decision:article 1the conditional marketing authorisation granted by decision c(2020) 9284(final) of 14 december 2020 is renewed without amendments.
 article 2the period of validity of the renewed authorisation shall be one year from 15 december 2022.
 article 3this decision is addressed to kite pharma eu b.v., tufsteen 1, 2132 nt hoofddorp, nederland.
 done at brussels, 15.11.2022
 for the commissionsandra gallina
 director-general</p></section></body></xml>